Glucocorticoids target the CXCL9/CXCL10-CXCR3 axis and confer protection against immune-mediated kidney injury
Standard
Glucocorticoids target the CXCL9/CXCL10-CXCR3 axis and confer protection against immune-mediated kidney injury. / Riedel, Jan-Hendrik; Robben, Lennart; Paust, Hans-Joachim; Zhao, Yu; Asada, Nariaki; Song, Ning; Peters, Anett; Kaffke, Anna; Borchers, Alina C; Tiegs, Gisa; Seifert, Larissa; Tomas, Nicola M; Hoxha, Elion; Wenzel, Ulrich O; Huber, Tobias B; Wiech, Thorsten; Turner, Jan-Eric; Krebs, Christian F; Panzer, Ulf.
In: JCI INSIGHT, Vol. 8, No. 1, e160251, 10.01.2023.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Glucocorticoids target the CXCL9/CXCL10-CXCR3 axis and confer protection against immune-mediated kidney injury
AU - Riedel, Jan-Hendrik
AU - Robben, Lennart
AU - Paust, Hans-Joachim
AU - Zhao, Yu
AU - Asada, Nariaki
AU - Song, Ning
AU - Peters, Anett
AU - Kaffke, Anna
AU - Borchers, Alina C
AU - Tiegs, Gisa
AU - Seifert, Larissa
AU - Tomas, Nicola M
AU - Hoxha, Elion
AU - Wenzel, Ulrich O
AU - Huber, Tobias B
AU - Wiech, Thorsten
AU - Turner, Jan-Eric
AU - Krebs, Christian F
AU - Panzer, Ulf
PY - 2023/1/10
Y1 - 2023/1/10
N2 - Glucocorticoids remain a cornerstone of therapeutic regimes for autoimmune and chronic inflammatory diseases - for example, in different forms of crescentic glomerulonephritis - because of their rapid antiinflammatory effects, low cost, and wide availability. Despite their routine use for decades, the underlying cellular mechanisms by which steroids exert their therapeutic effects need to be fully elucidated. Here, we demonstrate that high-dose steroid treatment rapidly reduced the number of proinflammatory CXCR3+CD4+ T cells in the kidney by combining high-dimensional single-cell and morphological analyses of kidney biopsies from patients with antineutrophil cytoplasmic antibody-associated (ANCA-associated) crescentic glomerulonephritis. Using an experimental model of crescentic glomerulonephritis, we show that the steroid-induced decrease in renal CD4+ T cells is a consequence of reduced T cell recruitment, which is associated with an ameliorated disease course. Mechanistic in vivo and in vitro studies revealed that steroids act directly on renal tissue cells, such as tubular epithelial cells, but not on T cells, which resulted in an abolished renal expression of CXCL9 and CXCL10 as well as in the prevention of CXCR3+CD4+ T cell recruitment to the inflamed kidneys. Thus, we identified the CXCL9/CXCL10-CXCR3 axis as a previously unrecognized cellular and molecular target of glucocorticoids providing protection from immune-mediated pathology.
AB - Glucocorticoids remain a cornerstone of therapeutic regimes for autoimmune and chronic inflammatory diseases - for example, in different forms of crescentic glomerulonephritis - because of their rapid antiinflammatory effects, low cost, and wide availability. Despite their routine use for decades, the underlying cellular mechanisms by which steroids exert their therapeutic effects need to be fully elucidated. Here, we demonstrate that high-dose steroid treatment rapidly reduced the number of proinflammatory CXCR3+CD4+ T cells in the kidney by combining high-dimensional single-cell and morphological analyses of kidney biopsies from patients with antineutrophil cytoplasmic antibody-associated (ANCA-associated) crescentic glomerulonephritis. Using an experimental model of crescentic glomerulonephritis, we show that the steroid-induced decrease in renal CD4+ T cells is a consequence of reduced T cell recruitment, which is associated with an ameliorated disease course. Mechanistic in vivo and in vitro studies revealed that steroids act directly on renal tissue cells, such as tubular epithelial cells, but not on T cells, which resulted in an abolished renal expression of CXCL9 and CXCL10 as well as in the prevention of CXCR3+CD4+ T cell recruitment to the inflamed kidneys. Thus, we identified the CXCL9/CXCL10-CXCR3 axis as a previously unrecognized cellular and molecular target of glucocorticoids providing protection from immune-mediated pathology.
U2 - 10.1172/jci.insight.160251
DO - 10.1172/jci.insight.160251
M3 - SCORING: Journal article
C2 - 36355429
VL - 8
JO - JCI INSIGHT
JF - JCI INSIGHT
SN - 2379-3708
IS - 1
M1 - e160251
ER -